TNFRSF4

TNFRSF4 (OX40/CD134) is an inducible T-cell costimulatory receptor that signals through TRAF2/TRAF5-mediated NF-κB activation^[1]. Mechanistically, OX40 supports antigen-driven CD4⁺ T-cell persistence by maintaining BCL2 and BCL2L1/BCL-xL expression, while sustained survivin expression drives clonal expansion^[2]^[3]. In disease models, the OX40L-OX40 axis promotes aberrant T follicular helper responses in systemic lupus erythematosus and marks immune escape by Tnfrsf4-expressing regulatory T cells in chronic myeloid leukemia^[4]^[5]. Compared with membrane OX40, a soluble OX40 isoform has been identified in serum from healthy donors and patients with autoimmune disease or cancer, supporting isoform-aware assay design^[6]. For experimental applications, anti-OX40 agonist antibodies such as MOXR0916 have been evaluated in advanced solid tumors to test effector T-cell costimulation and regulatory T-cell modulation^[7].

References:

[1]. Kawamata S, et al. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J Biol Chem. 1998 Mar 6;273(10):5808-14. [Content Brief]

[2]. Rogers PR, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001 Sep;15(3):445-55. [Content Brief]

[3]. Song J, et al. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity. 2005 May;22(5):621-31. [Content Brief]

[4]. Jacquemin C, et al. OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response. Immunity. 2015 Jun 16;42(6):1159-70. [Content Brief]

[5]. Hinterbrandner M, et al. Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. JCI Insight. 2021;6(23):e151797.

[6]. Taylor L, et al. Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay. J Immunol Methods. 2001 Sep 1;255(1-2):67-72. [Content Brief]

[7]. Kim TW, et al. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Aug 15;28(16):3452-3463. [Content Brief]

TNFRSF4 Related Products (5):

By Effects:	Inhibitors (4) Agonist (1)

Cat. No.	Product Name	Effect	Purity

HY-P992132

Solaprubart	Inhibitor	99.59%
Solaprubart is a humanized IgG1-κ monoclonal antibody targeting TNFSF4/OX40L. Solaprubart regulates immune homeostasis by blocking the OX40L-OX40 signaling pathway and can be used for the research of autoimmune diseases such as atopic dermatitis.

HY-P992435

OX118	Inhibitor
OX118 is a fully human, ADCC-enhanced monoclonal antibody targeting OX40L, the recommended isotype control is HY-P99001. OX118 blocks OX40L, suppresses effector T-cell proliferation, expands regulatory T-cell populations, and reduces bystander activation across natural killer cells, B cells, and CD14+ monocytes. OX118 can be used for the research of graft-versus-host disease.

HY-P992368

HLX51	Agonist
HLX51 is a regulatory T cell inhibitor and OX40/CD134/TNFRSF4 agonist with tumour growth inhibitory activity. HLX51 inhibits regulatory T cell differentiation and activity, relieves tumour microenvironment immunosuppression, enhances effector T cell function. HLX51 competitively binds OX40, activates OX40, promotes immune cell proliferation and T cell killing ability. HLX51 modulates immune cell function to inhibit tumour growth. HLX51 can be used for the research of advanced/metastatic solid tumours and lymphomas.

HY-P992415

MSB013	Inhibitor
MSB013 is a recombinant antibody targeting CD134.

HY-P991614

IBI356	Inhibitor
IBI356 is a humanized monoclonal antibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis.

Name
Email *

	Sorry, but the email address you supplied was invalid.